Mesoblast Limited · ASX:MSB

Mesoblast — Shareholder Meeting (September 2010)

18 slides from Mesoblast's shareholder meeting presentation, Sep 22, 2010

  1. Slide 1: Speech by Chairman Brian Jamieson to Extraordinary General Meeting

    For personal use only SPEECH BY MESOBLAST CHAIRMAN BRIAN JAMIESON TO EXTRAORDINARY GENERAL MEETING Welcome to this Extraordinary General Meeting of Mesoblast Limited. Today is a very significant landmark in Mesoblast’s short history; one that I am certain will be regarded as a major milestone for ou

  2. Slide 2: Chairman's speech continued: Angioblast acquisition

    At the same time, our associate company in the United States, Angioblast Systems Inc., has also had remarkable achievements in its objectives to commercialise the shared stem cell technology platform for a range of non-orthopaedic applications, including heart diseases, oncology, diabetes, and eye d

  3. Slide 3: Chairman's speech: independent expert report and resolutions

    • A simplified corporate structure with a larger base of issued share capital would be expected to create greater shareholder value through greater liquidity, inclusion in indices, exposure to new investors, and ultimately access to greater pools of capital. The terms of the acquisition have been re

  4. Slide 4: Extraordinary General Meeting

    For personal use only Extraordinary General Meeting Melbourne September 22, 2010

  5. Slide 5: Commercializing Stem Cells: Our Patented Technology Underpins the Right Business Model

    For personal use only Commercializing Stem Cells: Our Patented Technology Underpins the Right Business Model Embryonic Stem Cells/iPS Cells • Research only • NO near-term therapeutic product (ethics, cancer risk, etc.) Adult Stem Cells • Commercial products in the clinic today • Most adult stem cell

  6. Slide 6: Our Industrial-Scale Manufacturing Process

    Our Industrial-Scale Manufacturing Process For personal use only Bone Marrow (BM) from universal donor BM + stem cell-binding antibody magnetic beads Competitive Advantages of Manufacturing Process: • homogeneous cell population magnet • well-controlled cell expansion • efficient large-scale expansi

  7. Slide 7: We Own the Intellectual Property on Mesenchymal Precursor Cells

    We Own the Intellectual Property on Mesenchymal Precursor Cells (MPC) For personal use only bone marrow + antibody Products For bone Orthopaedic magnetic Diseases beads cartilage MPC Highly Expandable + Non-Immunogenic magnet Products For Eye Diseases heart Products For Isolated Culture-expanded mus

  8. Slide 8: Mesenchymal Precursor Cell (MPC) Technology Platform

    For personal use only Mesenchymal Precursor Cell (MPC) Technology Platform Royalty stream ANGIOBLAST IMVS/Hanson Institute Assignment of MPC Systems, Inc. (Australia) Intellectual Property (USA) cardiac, eye, Royalty stream oncology, diabetes MPC License for + other applications Orthopaedic Sharehol

  9. Slide 9: What Are The Strategic Benefits Of The Proposed Transaction?

    For personal use only What Are The Strategic Benefits Of The Proposed Transaction?

  10. Slide 10: Increased Shareholder Value

    For personal use only Increased Shareholder Value Fund Raisings $m IPO @ 50 cents 21.0 Issued shares (subject to EGM) 250m Equity Placements: Current Share Price $2.50 Jul-06 17.4 Cash available after EGM (circa) $41m Dec-07 13.4 Market Cap (circa) $625m Apr-09 10.8 May-10 37.0 Options + Angioblast

  11. Slide 11: Increased Shareholder Value

    For personal use only Increased Shareholder Value

  12. Slide 12: Enhanced Revenue Generating Strategies

    For personal use only Enhanced Revenue Generating Strategies

  13. Slide 13: Enhanced Ability To Commercialize Technology

    For personal use only Enhanced Ability To Commercialize Technology 1. Taking Individual Applications to Market on Our Own e.g. Orphan Drug Applications 2. Broad-based Partnering of Platform Technology e.g. Pharma Licensing 3. Partnering Specific Applications e.g. Medtech Applications

  14. Slide 14: Enhanced Manufacturing Strategy Central To Maximizing Revenues

    For personal use only Enhanced Manufacturing Strategy Central To Maximizing Revenues

  15. Slide 15: Off-the-Shelf Product Portfolio Driving Value Creation

    For personal use only “Off-the-Shelf” Product Portfolio Driving Value Creation IND FDA Clearance Approval Lead Products Preclinical Phase I Phase II Phase III Bone Marrow Transplantation Congestive Heart Failure Spinal Fusion Knee Osteoarthritis Long Bone Fracture Repair Acute Myocardial Infarction

  16. Slide 16: United States Target Orthopedic Markets

    For personal use only United States Target Orthopedic Markets

  17. Slide 17: United States Non-Orthopaedic Markets

    For personal use only United States Non-Orthopaedic Markets

  18. Slide 18: Thank you for your loyalty and support!

    For personal use only Thank you for your loyalty and support!

Mesoblast — Shareholder Meeting (September 2010) on 6ix